



REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad - 500 081, Telangana, INDIA.

Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com
CIN: L24110TG1991PLC012471

Dated May 16, 2018

To,
National Stock Exchange of India Limited
BSE Limited
Symbol: NSE: GRANULES; BSE: 532482

Sub: Receipt of Establishment Inspection Report (EIR) US FDA -Reg.

Ref: Our letter dated 26th March 2018 under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

Please be informed that, US FDA has issued Establishment Inspection Report (EIR) for Company's Jeedimetla facility located at Hyderabad, Telangana, India.

This facility was inspected by US FDA in March 2018 and there was one (1) 483 observation during the inspection. The company has responded to the observation within the stipulated timeframe. Jeedimetla facility manufactures Active pharmaceutical ingredients (APIs) and Pharmaceutical Formulation Intermediates (PFIs).

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours faithfully,

For GRANULES INDIA LIMITED



**CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)**